Novo Nordisk A/S
NONOF
$76.68
$1.061.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 20.61% | 27.14% | 37.16% | 51.42% | 54.37% |
| Total Depreciation and Amortization | 17.24% | 19.82% | 36.35% | 33.97% | 14.19% |
| Total Amortization of Deferred Charges | 18.52% | 14.80% | 14.80% | 14.80% | 14.80% |
| Total Other Non-Cash Items | -23.52% | 36.67% | -62.96% | -77.00% | 45.91% |
| Change in Net Operating Assets | 7.34% | -705.81% | 104.64% | 28.38% | -189.27% |
| Cash from Operations | 11.11% | 11.55% | 31.45% | 13.66% | 40.77% |
| Capital Expenditure | -82.46% | -91.96% | -86.66% | -100.67% | -120.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 90.08% | 90.08% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.63% | 22.54% | -12.73% | 47.20% | -230.80% |
| Cash from Investing | -190.78% | -23.89% | -32.43% | -17.08% | -84.01% |
| Total Debt Issued | -- | 36,354.74% | 52,996.92% | -- | -- |
| Total Debt Repaid | -331.83% | -368.34% | -335.35% | -4.82% | 89.23% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 32.56% | 18.96% | -0.02% | -11.10% | -24.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -40.21% | -40.21% | -55.16% | -55.16% | -25.46% |
| Other Financing Activities | -- | -- | -- | 194.97% | -- |
| Cash from Financing | 112.20% | 36.00% | 26.10% | -34.01% | -23.78% |
| Foreign Exchange rate Adjustments | 485.36% | 32.55% | 141.94% | 144.37% | 49.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.51% | 841.37% | 4,664.26% | -511.65% | -19.98% |
